石明博士為和黃醫(yī)藥執(zhí)行副總裁、研發(fā)負(fù)責(zé)人兼首席醫(yī)學(xué)官。他負(fù)責(zé)帶領(lǐng)公司的藥物發(fā)現(xiàn)和臨床開發(fā)戰(zhàn)略和執(zhí)行。
于2022年加入和黃醫(yī)藥前，石博士曾任創(chuàng)勝集團(tuán)的全球研發(fā)負(fù)責(zé)人兼首席醫(yī)學(xué)官，在中國和美國建立了一個(gè)強(qiáng)大的全球研發(fā)團(tuán)隊(duì)，并將七個(gè)項(xiàng)目推進(jìn)臨床開發(fā)及多項(xiàng)臨床前候選藥物提名。在此之前，石博士在諾華工作超過15 年，擔(dān)任過多個(gè)高級(jí)領(lǐng)導(dǎo)人員職位，包括全球項(xiàng)目臨床負(fù)責(zé)人，并在多個(gè)新型腫瘤/ 血液病產(chǎn)品的臨床開發(fā)中發(fā)揮了關(guān)鍵領(lǐng)導(dǎo)作用，包括從臨床概念驗(yàn)證到成功執(zhí)行全球關(guān)鍵試驗(yàn)、產(chǎn)品注冊和生命周期管理。
石博士擁有南加州大學(xué)分子藥理學(xué)和毒理學(xué)博士學(xué)位，并于哈佛大學(xué)醫(yī)學(xué)院進(jìn)行博士后研究。他在北京協(xié)和醫(yī)學(xué)院完成其醫(yī)學(xué)學(xué)位。
Dr Michael Shi is the Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED. He oversees the drug discovery and development of the company from strategy to execution.
Prior to joining HUTCHMED in 2022, Dr Shi was the Global Head of R&D and Chief Medical Officer at Transcenta Holding Limited where he helped build a strong global research and development organization across China and the U.S. and advanced seven programs into clinical development and multiple preclinical candidate nominations. Before that, Dr Shi worked at Novartis for over 15 years, where he held various senior leadership positions including global program clinical head in clinical development. He played key leadership roles in the clinical development of multiple novel oncology/hematology products from clinical proof-of-concept to successful execution of global pivotal trials, product registration and lifecycle management.?
Dr Shi holds a PhD in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.